Ignite Creation Date:
2025-12-24 @ 7:59 PM
Ignite Modification Date:
2025-12-25 @ 5:33 PM
Study NCT ID:
NCT03403504
Status:
COMPLETED
Last Update Posted:
2020-01-31
First Post:
2016-07-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
OTR Tablet 10 mg Fasted-state Bioequivalence Study
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D059350', 'term': 'Chronic Pain'}], 'ancestors': [{'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D018045', 'term': 'Receptors, Oxytocin'}, {'id': 'D013607', 'term': 'Tablets'}, {'id': 'D010098', 'term': 'Oxycodone'}], 'ancestors': [{'id': 'D043562', 'term': 'Receptors, G-Protein-Coupled'}, {'id': 'D011956', 'term': 'Receptors, Cell Surface'}, {'id': 'D008565', 'term': 'Membrane Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D018013', 'term': 'Receptors, Neuropeptide'}, {'id': 'D017981', 'term': 'Receptors, Neurotransmitter'}, {'id': 'D018000', 'term': 'Receptors, Peptide'}, {'id': 'D011979', 'term': 'Receptors, Pituitary Hormone'}, {'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D003061', 'term': 'Codeine'}, {'id': 'D009022', 'term': 'Morphine Derivatives'}, {'id': 'D009019', 'term': 'Morphinans'}, {'id': 'D053610', 'term': 'Opiate Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D010616', 'term': 'Phenanthrenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'rongna.a@mundipharma.com.cn', 'phone': '86 10 65636885', 'title': 'Rongna. A', 'organization': 'Mundipharma(China) Pharmaceutical. Co. Ltd'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': "Events will be recorded from the point at which the ICF is signed until 7±1 days after last oxycodone dose in the case of completion/discontinuation from the study. This includes new AEs that are reported within 7±1 days after last oxycodone dosing after the subject's completion/discontinuation visit. AE data has been collected for 35 days since ICF signed up to follow-up visit for study completion of each subject.", 'description': 'same with clinicaltrials.gov Definitions.', 'eventGroups': [{'id': 'EG000', 'title': 'OTR 10 mg', 'description': 'the treatment group with OTR 10 mg', 'otherNumAtRisk': 23, 'deathsNumAtRisk': 23, 'otherNumAffected': 7, 'seriousNumAtRisk': 23, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'OXYCONTIN 10 mg', 'description': 'the treatment group with OXYCONTIN 10 mg', 'otherNumAtRisk': 23, 'deathsNumAtRisk': 23, 'otherNumAffected': 0, 'seriousNumAtRisk': 23, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Heart rate decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 23, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 23, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'WBC urine positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 23, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 23, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cmax of OTR 10 mg', 'description': 'the treatment group with OTR 10 mg'}, {'id': 'OG001', 'title': 'Cmax of OXYCONTIN 10 mg', 'description': 'the treatment group with OXYCONTIN 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '11.617', 'groupId': 'OG000', 'lowerLimit': '8.5821', 'upperLimit': '14.6519'}, {'value': '10.564', 'groupId': 'OG001', 'lowerLimit': '8.3103', 'upperLimit': '12.8177'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters Cmax of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.', 'unitOfMeasure': 'ng/ml', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'AUCt of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'AUCt of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'AUCt of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '123.5608', 'groupId': 'OG000', 'lowerLimit': '93.4687', 'upperLimit': '153.6529'}, {'value': '124.0294', 'groupId': 'OG001', 'lowerLimit': '98.1652', 'upperLimit': '149.8936'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters AUCt of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.', 'unitOfMeasure': 'ng*h/ml', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'AUCINF of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'AUCINF of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'AUCINF of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '125.7605', 'groupId': 'OG000', 'lowerLimit': '94.4572', 'upperLimit': '157.0638'}, {'value': '127.4811', 'groupId': 'OG001', 'lowerLimit': '100.0286', 'upperLimit': '154.9336'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters AUCINF for analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) was used to compare the test and the reference treatments.', 'unitOfMeasure': 'ng*h/ml', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Adverse Events of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adverse Events of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'Adverse Events of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'title': 'Number of AEs', 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}]}, {'title': 'Number of TEAEs', 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}]}, {'title': 'Number of related TEAEs', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 35 days', 'description': 'An overall summary of the number and percentage of Adverse Events will be provided for each treatment groups to assess the safety of OTR tablet 10 mg and OXYCONTIN tablet 10 mg.', 'unitOfMeasure': 'AEs', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of AEs Related to Vital Signs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Vital Signs of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'Vital Signs of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 35 days', 'description': 'Vital sign parameters( systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature)to be summarised on the rate of lower than, within, and higher than the reference range values from baseline to end of study.', 'unitOfMeasure': 'AEs of vital signs related', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of AEs Related to ECGs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'ECG of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg and OXYCONTIN tablet 10 mg'}, {'id': 'OG001', 'title': 'ECG of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 35 days', 'description': 'Twelve-lead ECG was conducted at screening and on Day 4 of Period 2.', 'unitOfMeasure': 'AEs related to ECGs', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Lab Tests With Clinical Significance', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Clinical Laboratory Data of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'Clinical Laboratory Data of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 35 days', 'description': 'Clinical laboratory data (hematology, blood chemistry, and urinalysis) to be summarized on the rate of lower than, within, and higher than the reference range values from baseline to end of study.', 'unitOfMeasure': 'lab tests with clinical significance', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of AEs Related to Physical Examination', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Physical Examinations of OTR Tablet 10 mg', 'description': 'OTR tablet 10 mg'}, {'id': 'OG001', 'title': 'Physical Examinations of OXYCONTIN Tablet 10 mg', 'description': 'OXYCONTIN tablet 10 mg'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 35 days', 'description': 'Physical examination was conducted at screening, and on Day -1, Day 4 in each Period.', 'unitOfMeasure': 'AEs related to physical examinations', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'OXYCONTIN 10 mg - OTR 10 mg', 'description': 'the treatment sequence is OXYCONTIN 10 mg dose first and then OTR 10 mg dose in fasted state'}, {'id': 'FG001', 'title': 'OTR 10 Mg-OXYCONTIN 10 mg', 'description': 'the treatment sequence is OTR 10 mg dose first and then OXYCONTIN 10 mg dose in fasted state'}], 'periods': [{'title': 'Period 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '12'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '11'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}, {'title': 'Period 2', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '11'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '11'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': '24, from Mar2017 to Jul2017, from patient database, medical clinic, advertisement recruitment and etc.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '24', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'OXYCONTIN 10 Mg-OTR 10 mg', 'description': 'the treatment sequence is OXYCONTIN 10 mg dose first and then OTR 10 mg dose'}, {'id': 'BG001', 'title': 'OTR 10 Mg-OXYCONTIN 10 mg', 'description': 'the treatment sequence is OTR 10 mg dose first and then OXYCONTIN 10 mg dose'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'title': 'Mean', 'categories': [{'measurements': [{'value': '36.9', 'spread': '10.18', 'groupId': 'BG000'}, {'value': '41.6', 'spread': '10.44', 'groupId': 'BG001'}, {'value': '39.3', 'spread': '10.36', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'HAN', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Weight', 'classes': [{'categories': [{'measurements': [{'value': '68.29', 'spread': '11.462', 'groupId': 'BG000'}, {'value': '64.25', 'spread': '9.536', 'groupId': 'BG001'}, {'value': '66.27', 'spread': '10.516', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Height', 'classes': [{'categories': [{'measurements': [{'value': '169.3', 'spread': '8.11', 'groupId': 'BG000'}, {'value': '167.9', 'spread': '5.70', 'groupId': 'BG001'}, {'value': '168.6', 'spread': '6.89', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'cm', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'BMI', 'classes': [{'categories': [{'measurements': [{'value': '23.72', 'spread': '2.888', 'groupId': 'BG000'}, {'value': '22.76', 'spread': '2.974', 'groupId': 'BG001'}, {'value': '23.24', 'spread': '2.908', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m2', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-05-16', 'size': 922482, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-10-12T03:38', 'hasProtocol': True}, {'date': '2018-01-30', 'size': 744102, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-10-12T04:36', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 24}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-01', 'completionDateStruct': {'date': '2017-09-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-01-15', 'studyFirstSubmitDate': '2016-07-26', 'resultsFirstSubmitDate': '2018-10-15', 'studyFirstSubmitQcDate': '2018-01-11', 'lastUpdatePostDateStruct': {'date': '2020-01-31', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-10-08', 'studyFirstPostDateStruct': {'date': '2018-01-18', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2019-10-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-07-24', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters Cmax of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.'}, {'measure': 'AUCt of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters AUCt of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.'}, {'measure': 'AUCINF of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State', 'timeFrame': 'up to 32 hours', 'description': 'The analysis was for PK parameters AUCINF for analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) was used to compare the test and the reference treatments.'}], 'secondaryOutcomes': [{'measure': 'Adverse Events of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State', 'timeFrame': 'up to 35 days', 'description': 'An overall summary of the number and percentage of Adverse Events will be provided for each treatment groups to assess the safety of OTR tablet 10 mg and OXYCONTIN tablet 10 mg.'}, {'measure': 'Number of AEs Related to Vital Signs', 'timeFrame': 'up to 35 days', 'description': 'Vital sign parameters( systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature)to be summarised on the rate of lower than, within, and higher than the reference range values from baseline to end of study.'}, {'measure': 'Number of AEs Related to ECGs', 'timeFrame': 'up to 35 days', 'description': 'Twelve-lead ECG was conducted at screening and on Day 4 of Period 2.'}, {'measure': 'Number of Lab Tests With Clinical Significance', 'timeFrame': 'up to 35 days', 'description': 'Clinical laboratory data (hematology, blood chemistry, and urinalysis) to be summarized on the rate of lower than, within, and higher than the reference range values from baseline to end of study.'}, {'measure': 'Number of AEs Related to Physical Examination', 'timeFrame': 'up to 35 days', 'description': 'Physical examination was conducted at screening, and on Day -1, Day 4 in each Period.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Chronic Pain']}, 'descriptionModule': {'briefSummary': 'This is an open-label, single Dose, randomised, cross-over study to confirm the bioequivalence (BE) of OTR tablet 10 mg and OXYCONTIN tablet 10 mg in a fasted state in Chinese subjects with chronic pain', 'detailedDescription': 'The investigation is designed as an open-label, single dose, randomized, and cross-over study to determine the PK profile of oxycodone from OTR tablet 10 mg and OXYCONTIN tablet 10 mg in Chinese subjects with chronic pain in a fasted state.\n\nthe China regulations for drug registration require that controlled medicine (opioid is categorized to be a controlled medicine) should not be applied in healthy volunteers in clinical studies. In this BE study, subjects with histories of chronic pain are chosen as the target population.\n\nInclusion/exclusion criteria are strictly defined to reduce the potential variation of the PK data. The subjects with abnormal liver and kidney functions, which may affect the metabolism of oxycodone.\n\nAs a general rule, cross-over design is applied in the study to decrease the inter-individual variations between the two cohorts. A washout period lasting for at least 7 half-lives of the investigational medicine is needed to eliminate the drug residual from the previous period\n\nopen label design is applied since the plasma concentration of oxycodone is to be objectively tested and analysed and randomization will be applied to reduce selection bias.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Chinese male or female subjects with histories of chronic pain regardless of the aetiology, aged 18-55 years both inclusive\n2. The average pain over the last 24 hours should be scored \\< 4 assessed with Numeric Rating Scales (NRS), when not receiving analgesics. The pain condition has been kept stable at least in the past 7 days prior to entering into the screening and is expected to be stable during the study duration\n3. Body weight ≥45 kg and a body mass index (BMI) ≥18 and ≤28 kg/m2\n4. Karnofsky score of Performance Status ≥70\n5. Willing to take all the food supplied while the subject is in the study unit\n6. Be able to read, understand, and sign written Informed Consent Form (ICF) prior to study participation and be willing to follow the protocol requirements\n7. Willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, some Intrauterine Device (IUD), sexual abstinence, or vasectomised partner\n8. Female subjects, including those up to less than one year post-menopausal, must have a negative serum pregnancy test and be non-lactating.\n\nExclusion Criteria:\n\n1. Subjects who are currently taking opioids or have used opioids in the past 14 days prior to receiving the study drug\n2. Have hypersensitivity history to any opioids, naltrexone, naloxone, or related compounds or any contraindications as detailed in the OTR and OXYCONTIN tablet Summary of Product Characteristics\n3. Histories of or any current conditions that might interfere with drug absorption, distribution, metabolism, or excretion\n4. Subjects who are likely to have paralytic ileus or acute abdomen or to require an operation on abdominal regions\n5. Subjects with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency\n6. Subjects with respiratory depression, corpulmonale, or chronic bronchial asthma\n7. Any history of seizures or symptomatic head trauma\n8. Subjects with abnormal liver function (values exceeding the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin during the Screening Phase) or abnormal renal function (values exceeding the ULN for serum creatinine during the Screening Phase). Note: if the values of ALT, AST or total bilirubin are between 1 to 1.2 times of ULN and confirmed not clinically significant by the Investigators, the subject may be recruited after getting the approval from Sponsor.\n9. Any other significant illness other than the primary disease of chronic pain during the 4 weeks preceding the entry into this study\n10. Subjects who are unable to stop taking monoamine oxidase inhibitors during this trial period or time lapses less than 2 weeks since drug withdrawal prior to the study drug administration\n11. Subjects who are currently taking tricyclic antidepressants or have used tricyclic antidepressants within 4 weeks prior to the study drug administration\n12. Subjects who have used any medicinal product which inhibits Cytochrome P450 3A4 (CYP3A4) (e.g. troleandomycin, ketoconazole, gestodene, etc.) or induces CYP3A4 (e.g. glucocorticoids, barbiturates, rifampicin, etc.) within 4 weeks prior to the study drug administration\n13. Subjects who have used any medicinal product which inhibits Cytochrome P450 2D6 (CYP2D6) (e.g. fluoxetine, quinidine, ritonavir, etc.) or induces CYP2D6 (e.g. dexamethasone, rifampicin, glutethimide, etc.) within 4 weeks prior to the study drug administration\n14. Histories of smoking (being a smoker or an occasional smoker) within 45 days prior to the study drug administration and refusal to abstain from smoking during the study. According to World Health Organization (WHO), a smoker is defined as having smoked at least 1 cigarette per day continuously for more than 6 months and an occasional smoker is defined as having smoked for more than 4 times per week and less than 1 cigarette per day continuously for more than 6 months.\n15. Subjects with histories of alcoholism or drug abuse. Alcoholism is defined as regular alcohol consumption exceeding 14 drinks/week (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor)\n16. Consumption of alcoholic beverages within 48 hours before study drug administration, and refusal to abstain from alcohol for at least 48 hours after study drug administration\n17. Refusal to abstain from food for 10 hours preceding and 4 hours following administration of the study drug and to abstain from caffeine or xanthine entirely during each confinement\n18. Positive Hepatitis B Surface Antigen (HBsAg), anti-Hepatitis C Virus (HCV), anti-Human Immunodeficiency Virus (HIV), or syphilis antibody test result\n19. Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, benzodiazepines, phencyclidine, methamphetamine, or cannabinoids. Or alcohol breath test is positive\n20. Any history of frequent nausea or emesis regardless of aetiology\n21. Blood or blood products donated within 30 days prior to administration of the study drugs or anytime during the study, except as required by this protocol\n22. Subjects who participated in a clinical research study within 30 days of study entry'}, 'identificationModule': {'nctId': 'NCT03403504', 'briefTitle': 'OTR Tablet 10 mg Fasted-state Bioequivalence Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'Mundipharma (China) Pharmaceutical Co. Ltd'}, 'officialTitle': 'An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 10 mg and OXYCONTIN® Tablet 10 mg in Chinese Subjects With Chronic Pain', 'orgStudyIdInfo': {'id': 'ONF16-CN-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Oxycodone Tamper Resistant', 'description': 'Oxycodone Tamper Resistant (OTR) Tablet 10 mg', 'interventionNames': ['Drug: Oxycodone Tamper Resistant']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'OXYCONTIN®', 'description': 'OXYCONTIN® Tablet 10 mg', 'interventionNames': ['Drug: OXYCONTIN®']}], 'interventions': [{'name': 'Oxycodone Tamper Resistant', 'type': 'DRUG', 'otherNames': ['Oxycodone Tamper Resistant (OTR) Tablet 10 mg'], 'description': 'Orally administered Oxycodone Tamper Resistant 10mg', 'armGroupLabels': ['Oxycodone Tamper Resistant']}, {'name': 'OXYCONTIN®', 'type': 'DRUG', 'otherNames': ['OXYCONTIN® Tablet 10 mg'], 'description': 'Orally administered OXYCONTIN® Tablet 10 mg', 'armGroupLabels': ['OXYCONTIN®']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shenyang', 'state': 'Liaoning', 'country': 'China', 'facility': 'The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}], 'overallOfficials': [{'name': 'Wenping Wang', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Affiliated Hospital of Liaoning University of Traditional Chinese Medicine'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'There is not a plan to make IPD available'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mundipharma (China) Pharmaceutical Co. Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}